HGF/c-met/Stat3 signaling during skin tumor cell invasion: Indications for a positive feedback loop

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Syed, Zanobia A ^a   Yin, Weihong ^a,b   Hughes, Kendall ^a   Gill, Jennifer N ^a   Shi, Runhua ^a   Clifford, John L ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; SCATTER FACTOR; STAT3 PROTEIN; SCATTER FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER INVASION; CELL ADHESION; CELL INVASION; CELL MEMBRANE; CELL MOTILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; POSITIVE FEEDBACK; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SKIN TUMOR; ANIMAL; DRUG ANTAGONISM; DRUG SCREENING; FEEDBACK SYSTEM; GENETICS; INTRACELLULAR SPACE; METABOLISM; MOUSE MUTANT; NUDE MOUSE; PATHOPHYSIOLOGY; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN TRANSPORT; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; FEEDBACK, PHYSIOLOGICAL; FEMALE; HEPATOCYTE GROWTH FACTOR; HUMANS; INTRACELLULAR SPACE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, NUDE; MICE, SCID; NEOPLASM INVASIVENESS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; STAT3 TRANSCRIPTION FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79956055536     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-180     Document Type: Article

References (56)

1. Ihle JN. The Stat family in cytokine signaling. Curr Opin Cell Biol 2001, 13(2):211. 10.1016/S0955-0674(00)00199-X, 11248555.
2. Williams JG. STAT signalling in cell proliferation and in development. Curr Opin Genet Dev 2000, 10(5):503. 10.1016/S0959-437X(00)00119-2, 10980427.
3. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000, 19(21):2474. 10.1038/sj.onc.1203527, 10851046.
4. Bromberg J. Stat proteins and oncogenesis. J Clin Invest 2002, 109(9):1139. 150969, 11994401.
5. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell JE. Stat3 as an Oncogene. Cell 1999, 98(3):295. 10.1016/S0092-8674(00)81959-5, 10458605.
6. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007, 7(1):41. 10.1038/nri1995, 17186030.
7. Masuda M, Suzui M, Yasumatu R, Nakashima T, Kuratomi Y, Azuma K, Tomita K, Komiyama S, Weinstein IB. Constitutive Activation of Signal Transducers and Activators of Transcription 3 Correlates with Cyclin D1 Overexpression and May Provide a Novel Prognostic Marker in Head and Neck Squamous Cell Carcinoma. Cancer Res 2002, 62(12):3351-3355.
8. Bowman T, Broome MA, Sinibaldi D, Wharton W, Pledger WJ, Sedivy JM, Irby R, Yeatman T, Courtneidge SA, Jove R. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci USA 2001, 98(13):7319-7324. 10.1073/pnas.131568898, 34666, 11404481.
9. Zushi S, Shinomura Y, Kiyohara T, Miyazaki Y, Kondo S, Sugimachi M, Higashimoto Y, Kanayama S, Matsuzawa Y. STAT3 mediates the survival signal in oncogenic ras-transfected intestinal epithelial cells. Int J Cancer 1998, 78(3):326-330. 10.1002/(SICI)1097-0215(19981029)78:3<326::AID-IJC12>3.0.CO;2-4, 9766567.
10. Aoki Y, Feldman GM, Tosato G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 2003, 101(4):1535-1542. 10.1182/blood-2002-07-2130, 12393476.
11. Bhattacharya S, Ray RM, Johnson LR. STAT3-mediated transcription of Bcl-2, Mcl-1 and c-IAP2 prevents apoptosis in polyamine-depleted cells. Biochem J 2005, 392(2):335-344. 10.1042/BJ20050465, 1316269, 16048438.
12. Dechow TN, Pedranzini L, Leitch A, Leslie K, Gerald WL, Linkov I, Bromberg JF. Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc Natl Acad Sci USA 2004, 101(29):10602-10607. 10.1073/pnas.0404100101, 489981, 15249664.
13. Itoh M, Murata T, Suzuki T, Shindoh M, Nakajima K, Imai K, Yoshida K. Requirement of STAT3 activation for maximal collagenase-1 (MMP-1) induction by epidermal growth factor and malignant characteristics in T24 bladder cancer cells. Oncogene 2005, 25(8):1195.
14. Xie T, Wei D, Liu M, Gao AC, Ali-Osman F, Sawaya R, Huang S. Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 2004, 23(20):3550. 10.1038/sj.onc.1207383, 15116091.
15. Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Shumin Z, Wang T, Sinibaldi D, Coppola D, et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002, 21(13):2000. 10.1038/sj.onc.1205260, 11960372.
16. Hung W, Elliott B. Co-operative Effect of c-Src Tyrosine Kinase and Stat3 in Activation of Hepatocyte Growth Factor Expression in Mammary Carcinoma Cells. J Biol Chem 2001, 276(15):12395-12403. 10.1074/jbc.M010715200, 11278729.
17. Galm O, Yoshikawa H, Esteller M, Osieka R, Herman JG. SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood 2003, 101(7):2784-2788. 10.1182/blood-2002-06-1735, 12456503.
18. Yoshikawa H, Matsubara K, Qian GS, Jackson P, Groopman JD, Manning JE, Harris CC, Herman JG. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet 2001, 28(1):29.
19. Chan KS, Carbajal S, Kiguchi K, Clifford J, Sano S, DiGiovanni J. Epidermal Growth Factor Receptor-Mediated Activation of Stat3 during Multistage Skin Carcinogenesis. Cancer Res 2004, 64(7):2382-2389. 10.1158/0008-5472.CAN-03-3197, 15059889.
20. Zhang Y, Wang L, Jove R, Vande Woude G. Requirement of Stat3 for HGF/SF-Met mediated tumorigenesis. Oncogene 2002, 21(2):217-226. 10.1038/sj.onc.1205004, 11803465.
21. Sherry MM, Reeves A, Wu JK, Cochran BH. STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem Cells 2009, 27(10):2383-2392. 10.1002/stem.185, 19658181.
22. Darnell JE. Validating Stat3 in cancer therapy. Nat Med 2005, 11(6):595-596. 10.1038/nm0605-595, 15937466.
23. Kortylewski M, Swiderski P, Herrmann A, Wang L, Kowolik C, Kujawski M, Lee H, Scuto A, Liu Y, Yang C, et al. In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol 2009, 27(10):925-932. 10.1038/nbt.1564, 2846721, 19749770.
24. Pedranzini L, Leitch A, Bromberg J. Stat3 is required for the development of skin cancer. J Clin Invest 2004, 114(5):619. 514594, 15343379.
25. Chan KS, Sano S, Kiguchi K, Anders J, Komazawa N, Takeda J, DiGiovanni J. Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. J Clin Invest 2004, 114(5):720. 514583, 15343391.
26. Kataoka K, Kim DJ, Carbajal S, Clifford JL, DiGiovanni J. Stage-specific disruption of Stat3 demonstrates a direct requirement during both the initiation and promotion stages of mouse skin tumorigenesis. Carcinogenesis 2008, 29(6):1108-1114. 10.1093/carcin/bgn061, 2902397, 18453544.
27. Sano S, Chan KS, Carbajal S, Clifford J, Peavey M, Kiguchi K, Itami S, Nickoloff BJ, DiGiovanni J. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med 2005, 11(1):43. 10.1038/nm1162, 15592573.
28. Kim DJ, Kataoka K, Rao D, Kiguchi K, Cotsarelis G, Digiovanni J. Targeted disruption of stat3 reveals a major role for follicular stem cells in skin tumor initiation. Cancer Res 2009, 69(19):7587-7594. 10.1158/0008-5472.CAN-09-1180, 19738054.
29. Kim DJ, Chan KS, Sano S, DiGiovanni J. Signal transducer and activator of transcription 3 (Stat3) in epithelial carcinogenesis. Molecular Carcinogenesis 2007, 46(8):725-731. 10.1002/mc.20342, 17610223.
30. Sano S, Chan KS, DiGiovanni J. Impact of Stat3 activation upon skin biology: A dichotomy of its role between homeostasis and diseases. J Dermatol Sci 2008, 50(1):1-14. 10.1016/j.jdermsci.2007.05.016, 17601706.
31. Suiqing C, Min Z, Lirong C. Overexpression of Phosphorylated-STAT3 Correlated with the Invasion and Metastasis of Cutaneous Squamous Cell Carcinoma. J Dermatol Sci 2005, 32(5):354-360.
32. Clifford J, Walch E, Yang X, Xu X, Alberts D, Clayman G, El-Naggar A, Lotan R, Lippman S. Suppression of type I interferon signaling proteins is an early event in squamous skin carcinogenesis. Clin Cancer Res 2002, 8(7):2067-2072.
33. Kusaba T, Nakayama T, Yamazumi K, Yakata Y, Yoshizaki A, Nagayasu T, Sekine I. Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors. J Clin Pathol 2005, 58(8):833-838. 10.1136/jcp.2004.023416, 1770863, 16049285.
34. Kira M, Sano S, Takagi S, Yoshikawa K, Takeda J, Itami S. STAT3 Deficiency in Keratinocytes Leads to Compromised Cell Migration through Hyperphosphorylation of p130cas. J Biol Chem 2002, 277(15):12931-12936. 10.1074/jbc.M110795200, 11812786.
35. Gherardi E, Stoker M. Hepatocyte growth factor-scatter factor: mitogen, motogen, and met. Cancer Cells 1991, 3(6):227-232.
36. Cortner J, Vande Woode G, Rong S. The Met-HGF/SF autocrine signaling mechanism is involved in sarcomogenesis. EXS 1995, 74:89-121.
37. Di Renzo MF, Olivero M, Martone T, Maffe A, Maggiora P, De Stefani A, Valente G, Giordano S, Cortesina G, Comoglio PM. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 2000, 19(12):1547-1555. 10.1038/sj.onc.1203455, 10734314.
38. Ma PC, Kijima T, Maulik G, Fox EA, Sattler M, Griffin JD, Johnson BE, Salgia R. c-MET Mutational Analysis in Small Cell Lung Cancer: Novel Juxtamembrane Domain Mutations Regulating Cytoskeletal Functions. Cancer Res 2003, 63(19):6272-6281.
39. Boccaccio C, Ando M, Tamagnone L, Bardelli A, Michieli P, Battistini C, Comoglio PM. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature 1998, 391(6664):285-288. 10.1038/34657, 9440692.
40. Cramer A, Kleiner S, Westermann M, Meissner A, Lange A, Friedrich K. Activation of the c-Met receptor complex in fibroblasts drives invasive cell behavior by signaling through transcription factor STAT3. Journal of Cellular Biochemistry 2005, 95(4):805-816. 10.1002/jcb.20459, 15838885.
41. Cheng N, Chytil A, Shyr Y, Joly A, Moses HL. Transforming growth factor-beta signaling-deficient fibroblasts enhance hepatocyte growth factor signaling in mammary carcinoma cells to promote scattering and invasion. Mol Cancer Res 2008, 6(10):1521-1533. 10.1158/1541-7786.MCR-07-2203, 2740918, 18922968.
42. Wojcik EJ, Sharifpoor S, Miller NA, Wright TG, Watering R, Tremblay EA, Swan K, Mueller CR, Elliott BE. A novel activating function of c-Src and Stat3 on HGF transcription in mammary carcinoma cells. Oncogene 2006, 25(19):2773-2784. 10.1038/sj.onc.1209306, 16407846.
43. Yin W, Cheepala S, Roberts J, Syson-Chan K, DiGiovanni J, Clifford J. Active Stat3 is required for survival of human squamous cell carcinoma cells in serum-free conditions. Molecular Cancer 2006, 5(1):15. 10.1186/1476-4598-5-15, 1502137, 16603078.
44. Caldenhoven E, van Dijk T, Solari R, Armstrong J, Raaijmakers J, Lammers J, Koenderman L, de Groot R. STAT3beta, a Splice Variant of Transcription Factor STAT3, Is a Dominant Negative Regulator of Transcription. J Biol Chem 1996, 271(22):13221-13227.
45. Schaefer T, Sanders L, Nathans D. Cooperative transcriptional activity of Jun and Stat3 beta, a short form of Stat3. Proc Natl Acad Sci USA 1995, 92(20):9097-9101. 10.1073/pnas.92.20.9097, 40931, 7568080.
46. Schaefer TS, Sanders LK, Park OK, Nathans D. Functional differences between Stat3alpha and Stat3beta. Mol Cell Biol 1997, 17(9):5307-5316. 232381, 9271408.
47. Gohda E, Kataoka H, Tsubouchi H, Daikilara Y, Yamamoto I. Phorbol ester-induced secretion of human hepatocyte growth factor by human skin fibroblasts and its inhibition by dexamethasone. FEBS Letters 1992, 301(1):107. 10.1016/0014-5793(92)80220-B, 1451778.
48. Syed Z, Cheepala SB, Gill JN, Stein J, Nathan CA, DiGiovanni J, Batra V, Adegboyega P, Kleiner HE, Clifford JL. All-trans retinoic acid suppresses Stat3 signaling during skin carcinogenesis. Cancer Prevention Research 2009, 2:903-911. 10.1158/1940-6207.CAPR-09-0041, 19789299.
49. Leong PL, Andrews GA, Johnson DE, Dyer KF, Xi S, Mai JC, Robbins PD, Gadiparthi S, Burke NA, Watkins SF, et al. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci USA 2003, 100(7):4138-4143. 10.1073/pnas.0534764100, 153061, 12640143.
50. Chen SY, Chen HC. Direct Interaction of Focal Adhesion Kinase (FAK) with Met Is Required for FAK To Promote Hepatocyte Growth Factor-Induced Cell Invasion. Mol Cell Biol 2006, 26(13):5155-5167. 10.1128/MCB.02186-05, 1489146, 16782899.
51. Silver DL, Naora H, Liu J, Cheng W, Montell DJ. Activated Signal Transducer and Activator of Transcription (STAT) 3: Localization in Focal Adhesions and Function in Ovarian Cancer Cell Motility. Cancer Res 2004, 64(10):3550-3558. 10.1158/0008-5472.CAN-03-3959, 15150111.
52. Gao SP, Bromberg JF. Touched and Moved by STAT3. Sci STKE 2006, 2006(343):pe30. 10.1126/stke.3432006pe30, 16835434.
53. Ng DCH, Lin BH, Lim CP, Huang G, Zhang T, Poli V, Cao X. Stat3 regulates microtubules by antagonizing the depolymerization activity of stathmin. J Cell Biol 2006, 172(2):245-257. 10.1083/jcb.200503021, 2063554, 16401721.
54. Gough DJ, Corlett A, Schlessinger K, Wegrzyn J, Larner AC, Levy DE. Mitochondrial STAT3 Supports Ras-Dependent Oncogenic Transformation. Science 2009, 324(5935):1713-1716. 10.1126/science.1171721, 2840701, 19556508.
55. Wegrzyn J, Potla R, Chwae YJ, Sepuri NBV, Zhang Q, Koeck T, Derecka M, Szczepanek K, Szelag M, Gornicka A, et al. Function of Mitochondrial Stat3 in Cellular Respiration. Science 2009, 323(5915):793-797. 10.1126/science.1164551, 2758306, 19131594.
56. Corvinus FM, Orth C, Moriggl R, Tsareva SA, Wagner S, Pfitzner EB, Baus D, Kaufmann R, Huber LA, Zatloukal K, et al. Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia 2005, 7(6):545-555. 10.1593/neo.04571, 1501283, 16036105.